Global and United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Market Analysis and Insights: Global and United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market
This report focuses on global and United States Duchenne Muscular Dystrophy (DMD) Therapeutics market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is estimated to be worth US$ 1936.4 million in 2022 and is forecast to a readjusted size of US$ 15940 million by 2028 with a CAGR of 42.1% during the review period. Fully considering the economic change by this health crisis, by Type, Exondys accounting for % of the Duchenne Muscular Dystrophy (DMD) Therapeutics global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Duchenne Muscular Dystrophy (DMD) Therapeutics market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented into
    Exondys
    Emflaza
    Translarna

Segment by Application, the Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented into
    Hospitals
    Clinics
    Home Care

Regional and Country-level Analysis
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy (DMD) Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Duchenne Muscular Dystrophy (DMD) Therapeutics business, the date to enter into the Duchenne Muscular Dystrophy (DMD) Therapeutics market, Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Sarepta Therapeutics
    PTC Therapeutics
    Pfizer
    Bristol-Myers Squibb
    Italfarmaco
    Santhera Pharmaceuticals

 1 Study Coverage
    1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size for the Year 2017-2028
        1.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size for the Year 2017-2028
    1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Duchenne Muscular Dystrophy (DMD) Therapeutics in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
        1.4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
        1.4.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
        1.4.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
        1.4.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Duchenne Muscular Dystrophy (DMD) Therapeutics by Type
    2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment by Type
        2.1.1 Exondys
        2.1.2 Emflaza
        2.1.3 Translarna
    2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017, 2022 & 2028)
    2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2028)
    2.4 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017, 2022 & 2028)
    2.5 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2028)

 3 Duchenne Muscular Dystrophy (DMD) Therapeutics by Application
    3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment by Application
        3.1.1 Hospitals
        3.1.2 Clinics
        3.1.3 Home Care
    3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017, 2022 & 2028)
    3.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2028)
    3.4 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017, 2022 & 2028)
    3.5 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2028)

 4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitor Landscape by Company
    4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Company
        4.1.1 Top Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Ranked by Revenue (2021)
        4.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Player (2017-2022)
    4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Concentration Ratio (CR)
        4.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Duchenne Muscular Dystrophy (DMD) Therapeutics in 2021
        4.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Headquarters, Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Headquarters and Area Served
        4.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Company
        4.5.1 Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2020, 2021 & 2022)

 5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region
    5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2028)
        5.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2017-2022
        5.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2017-2028
        6.1.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2017-2028
        6.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2017-2028
        6.4.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Sarepta Therapeutics
        7.1.1 Sarepta Therapeutics Company Details
        7.1.2 Sarepta Therapeutics Business Overview
        7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        7.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        7.1.5 Sarepta Therapeutics Recent Development
    7.2 PTC Therapeutics
        7.2.1 PTC Therapeutics Company Details
        7.2.2 PTC Therapeutics Business Overview
        7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        7.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        7.2.5 PTC Therapeutics Recent Development
    7.3 Pfizer
        7.3.1 Pfizer Company Details
        7.3.2 Pfizer Business Overview
        7.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        7.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        7.3.5 Pfizer Recent Development
    7.4 Bristol-Myers Squibb
        7.4.1 Bristol-Myers Squibb Company Details
        7.4.2 Bristol-Myers Squibb Business Overview
        7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        7.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        7.4.5 Bristol-Myers Squibb Recent Development
    7.5 Italfarmaco
        7.5.1 Italfarmaco Company Details
        7.5.2 Italfarmaco Business Overview
        7.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        7.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        7.5.5 Italfarmaco Recent Development
    7.6 Santhera Pharmaceuticals
        7.6.1 Santhera Pharmaceuticals Company Details
        7.6.2 Santhera Pharmaceuticals Business Overview
        7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        7.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        7.6.5 Santhera Pharmaceuticals Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
    Table 3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
    Table 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
    Table 5. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
    Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Player, 2017-2022
    Table 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2021)
    Table 15. Top Players of Duchenne Muscular Dystrophy (DMD) Therapeutics in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Sarepta Therapeutics Company Details
    Table 31. Sarepta Therapeutics Business Overview
    Table 32. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 33. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 34. Sarepta Therapeutics Recent Development
    Table 35. PTC Therapeutics Company Details
    Table 36. PTC Therapeutics Business Overview
    Table 37. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 38. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 39. PTC Therapeutics Recent Development
    Table 40. Pfizer Company Details
    Table 41. Pfizer Business Overview
    Table 42. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 43. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 44. Pfizer Recent Development
    Table 45. Bristol-Myers Squibb Company Details
    Table 46. Bristol-Myers Squibb Business Overview
    Table 47. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 48. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 49. Bristol-Myers Squibb Recent Development
    Table 50. Italfarmaco Company Details
    Table 51. Italfarmaco Business Overview
    Table 52. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 53. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 54. Italfarmaco Recent Development
    Table 55. Santhera Pharmaceuticals Company Details
    Table 56. Santhera Pharmaceuticals Business Overview
    Table 57. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 58. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 59. Santhera Pharmaceuticals Recent Development
    Table 60. Research Programs/Design for This Report
    Table 61. Key Data Information from Secondary Sources
    Table 62. Key Data Information from Primary Sources
List of Figures
    Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Picture
    Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 4. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 6. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share in Global 2017-2028
    Figure 7. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
    Figure 8. Product Picture of Exondys
    Figure 9. Product Picture of Emflaza
    Figure 10. Product Picture of Translarna
    Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type in 2022 & 2028
    Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2028) & (US$ Million)
    Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
    Figure 14. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type in 2022 & 2028
    Figure 15. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2028) & (US$ Million)
    Figure 16. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
    Figure 17. Product Picture of Hospitals
    Figure 18. Product Picture of Clinics
    Figure 19. Product Picture of Home Care
    Figure 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application in 2022 & 2028
    Figure 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2028) & (US$ Million)
    Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
    Figure 23. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application in 2022 & 2028
    Figure 24. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2028) & (US$ Million)
    Figure 25. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
    Figure 26. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 27. U.S. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 28. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 30. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 36. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Taiwan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Thailand Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Malaysia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Philippines Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 47. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 51. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 55. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 56. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 58. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 59. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 60. Bottom-up and Top-down Approaches for This Report
    Figure 61. Data Triangulation
    Figure 62. Key Executives Interviewed

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Market Analysis and Insights: Global and United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market
This report focuses on global and United States Duchenne Muscular Dystrophy (DMD) Therapeutics market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is estimated to be worth US$ 1936.4 million in 2022 and is forecast to a readjusted size of US$ 15940 million by 2028 with a CAGR of 42.1% during the review period. Fully considering the economic change by this health crisis, by Type, Exondys accounting for % of the Duchenne Muscular Dystrophy (DMD) Therapeutics global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Duchenne Muscular Dystrophy (DMD) Therapeutics market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented into
    Exondys
    Emflaza
    Translarna

Segment by Application, the Duchenne Muscular Dystrophy (DMD) Therapeutics market is segmented into
    Hospitals
    Clinics
    Home Care

Regional and Country-level Analysis
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy (DMD) Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Duchenne Muscular Dystrophy (DMD) Therapeutics business, the date to enter into the Duchenne Muscular Dystrophy (DMD) Therapeutics market, Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Sarepta Therapeutics
    PTC Therapeutics
    Pfizer
    Bristol-Myers Squibb
    Italfarmaco
    Santhera Pharmaceuticals